Whats new?
Download app
Access BlinkX everywhere across devices
Our updates are just like your noodles. Instant. You want?
Notifications can be turned off anytime from browser settings
Indegene Limited provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. The Company combines over two decades of healthcare domain expertise and its technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 31, 2023, the company had 65 active clients whom it caters to from six operation hubs and 17 offices located across North America, Europe and Asia.
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| 407.47 L | 239.33 L | 141.65 L | TBA | BSE | ₹ 1841.76 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 06 May, 24 | 08 May, 24 | 33 | ₹ 14,190 | Book Building | 13 May, 24 |
Details
| Sector | Type |
|---|---|
| Sector | Miscellaneous |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times |
|---|---|
| QIB | 197.55x |
| NII | 55.07x |
| Retail | 7.95x |
| Employee | 7.32x |
| Total | 69.91x |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 208.30 | 193.50 | 176.90 |
| EBITDA | 240.00 | 217.10 | 194.50 |
| PAT | 130.20 | 132.70 | 132.40 |
| Total Assets | 547.70 | 425.20 | 237.40 |
| Share Capital | 44.30 | 0.35 | 0.30 |
| Total Borrowings | 92.90 | 36.90 | 44.10 |
| Operating Activities (Net Cash) | 161.90 | 156.30 | 150.00 |
| Investing Activities (Net Cash) | 400.30 | 203.30 | 83.40 |
| Financing Activities (Net Cash) | 92.90 | 36.90 | 44.10 |
| Net Cashflow | 54.00 | 38.80 | 18.20 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
Indegene Limited was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of the Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by its Shareholders at the EGM held on February 29, 2016 the name of the Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of the Company was changed to better reflect the nature of business undertaken by the Company. Thereafter, the registered office of the Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, the Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by its Shareholders at the EGM held on November 7, 2022 and the name of the Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to the Company by the RoC, on November 17, 2022.
The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at Rs.138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or Rs.95.4 trillion (US$ 1.2 trillion) of such sales. Combined sales of biopharmaceutical companies and medical devices companies are estimated to reach Rs.163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at Rs.12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach Rs.15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales.
Peer Comparison:
Strengths
Risk
Strategy
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
From the list of open IPOs, select the IPO you want to invest.
Go through the IPO details like lot size, price band, about the company, etc.
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
